We report the safety and efficacy of 34 consecutive autologous bone marrow transplant (ABMT) procedures performed in adult patients with high-grade lymphoid malignancy after remission induction therapy. Fifteen patients with acute lymphoblastic leukemia (ALL) and six with high-grade non-Hodgkin’s lymphoma (NHL) received pretransplant conditioning with intravenous (IV) melphalan and fractionated total body irradiation (TBI). Thirteen other patients with NHL were conditioned with melphalan alone, having previously received local involved field radiotherapy. Unmanipulated noncryopreserved autologous marrow was reinjected within 48 hours of harvesting. Engraftment occurred in all patients with medians of 10 days of neutropenia (neutrophils <0.5 x 10^9/L), 4-day platelet transfusion requirement, 3 U packed RBC transfusion, and 18 days in hospital posttransplant. There were no procedure-related deaths. Actuarial disease-free survival in the 13 patients with ALL receiving autotransplant early in first remission is 48% with a median follow-up of 3 years. Two other ALL patients who had autotransplants after a period of maintenance therapy also remain in complete remission (CR). These results compare favorably with our 34% disease-free survival (DFS) in 15 allogeneic ALL transplant patients and 21% DFS in 19 patients on standard maintenance after a common induction schedule. No relapses have occurred in the 17 NHL patients transplanted in remission (median follow-up 2 years), but the two NHL patients who developed recurrent disease before ABMT died of progressive disease after temporary responses. We conclude that this method of ABMT results in rapid reengraftment with lack of toxicity and that the conditioning treatment used shows good efficacy against disease. It is applicable in high-grade lymphoid malignancy in first remission, and our results call into question the need for marrow purging in ALL and NHL patients transplanted in first remission.

© 1991 by The American Society of Hematology.
Median age for all patients was 30 years (range 18 to 58 years). Patient details are shown in Tables 1 and 2. Patients with ALL who received allogenic transplant (15) and standard maintenance (19) are also discussed for comparison.

The diagnosis of ALL was based on Romanowsky-stained smears of blood and BM, cytochemical staining including periodic acid-Schiff (PAS) and Sudan black reactions, and immunologic studies (Table 3). No cases were associated with antibody to HTLV-1 or HIV.

**ALL Details of Patient Population and Selection of Therapy**

From October 1982, a multidrug schedule for therapy in ALL patients aged more than 15 years was introduced in the Northeastern region of the UK. Designated NE ALL III, this is a 28-week induction and consolidation protocol described in detail previously. In our previous publications, we indicated that this therapy was used for all patients who were able to receive an aggressive protocol in our region, which has a population of 3.3 million. Between October 1982 and June 1988, the number of selected patients aged more than 15 years with ALL was 100. Twenty were excluded from the protocol and treated with palliative therapy only because of advanced age or death occurring within the first week of diagnosis. Of those receiving NE ALL III, 16 died in the first month or did not obtain remission. Nine patients either died in remission or developed recurrent leukemia before the end of the 28-week schedule. Three patients were resistant to standard induction and achieved remission with a regimen of cytosine arabinoside 1 g/m² twice daily for 3 days plus mitoxantrone, 12 mg/m² IV daily for three days (two courses). Thus, 55 patients reached the end of the 28-week schedule in established remission and were considered for secondary therapy at that time. Six patients were aged more than 55 years and were not considered for transplant. They received standard maintenance therapy but are not considered further in this study as it relates only to patients aged less than 55 years. The remaining 49 patients were allocated to the various forms of therapy as described below.

**Group I: NE ALL III plus standard maintenance (<55 years) 6mercaptopurine (6MP) and methotrexate (19).** From October 1982 to January 1984, all patients who were in CR at 28 weeks who did not have an allogenic donor received standard maintenance with daily oral 6MP 100 mg/m² (maximum 150 mg) and weekly oral methotrexate 15 mg/m² (maximum 20 mg) for 100 weeks. From 1984 to 1986 patients aged less than 30 years with WBC more than 50 x 10⁹/L who had a "common" ALL phenotype continued on this schedule; i.e., "good-risk" patients were kept on the standard maintenance. From 1986 to 1988 standard maintenance was used only for those patients aged more than 55 years because allogeneic or autologous transplant was offered to all patients aged less than 55 years and none of the patients refused these options.

**Group II: NE ALL III plus allogeneic transplant (15).** From March 1983, patients with ALL aged more than 15 and less than 45 years underwent tissue typing against their siblings and all those who had fully matched HLA-identical donors (16) were offered allogenic transplant in CR1. Only one patient (patient 7) who had an allogeneic donor preferred to have a autotransplant. The remaining 15 patients proceeded with this option. By chance, the median age of this group was substantially lower than that of patients in groups I and III, but they self-selected on the basis of tissue typing alone.

**Group III: NE ALL III plus autologous transplant with melphalan and TBI (13).** Owing to the observed high relapse rate in poor-risk patients on NE ALL III and standard maintenance in 1983 who were aged more than 30 years with WBC more than 50 x 10⁹/L, the melphalan/TBI autotransplant was introduced as an alternative consolidation with standard maintenance between 1984 and 1986 for such patients. Because of the lack of toxicity of this method, it was subsequently offered to all patients who did not have an allogenic donor who were aged more than 15 years less than 55 years from 1986 to 1988 regardless of risk features. No one offered an ABMT refused the procedure. We were able to perform ABMT on all patients fulfilling the criteria, and there was no problem of transplant delay owing to lack of marrow cellularity. The median time from diagnosis to autotransplant was 7.0 months (range 6 to 12 months).

**Group IV: NE ALL III plus maintenance plus ABMT (2).** One patient received NE ALL III, cranial irradiation, and 100 full weeks of maintenance. This patient then requested an autotransplant procedure that had just become available. An additional patient who underwent cranial irradiation had ABMT delayed as a result and continued on maintenance therapy until 6 weeks before

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age/Sex</th>
<th>Induction Treatment</th>
<th>Time From Diagnosis to ABMT (mo)</th>
<th>Days of Neutropenia &lt;0.5 x 10⁹/L</th>
<th>Days of Platelet Transfusion</th>
<th>Units of Blood Transfusion</th>
<th>Days in Hospital</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>45/F</td>
<td>NE ALL III + DCF</td>
<td>9</td>
<td>12</td>
<td>2</td>
<td>0</td>
<td>17</td>
<td>R d 822, D</td>
</tr>
<tr>
<td>2</td>
<td>51/M</td>
<td>NE ALL III</td>
<td>11</td>
<td>12</td>
<td>1</td>
<td>3</td>
<td>23</td>
<td>A/W d, 1,532+</td>
</tr>
<tr>
<td>3</td>
<td>48/F</td>
<td>NE ALL III</td>
<td>12</td>
<td>19</td>
<td>18</td>
<td>7</td>
<td>24</td>
<td>A/W d, 1,42+</td>
</tr>
<tr>
<td>4</td>
<td>18/M</td>
<td>NE ALL III</td>
<td>8</td>
<td>9</td>
<td>5</td>
<td>2</td>
<td>21</td>
<td>A/W d, 432, D</td>
</tr>
<tr>
<td>5</td>
<td>32/F</td>
<td>NE ALL III</td>
<td>6</td>
<td>10</td>
<td>6</td>
<td>18</td>
<td>A/W d, 184, D</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>34/F</td>
<td>NE ALL III</td>
<td>7</td>
<td>9</td>
<td>3</td>
<td>2</td>
<td>21</td>
<td>A/W d, 180, D</td>
</tr>
<tr>
<td>7</td>
<td>39/M</td>
<td>NE ALL III</td>
<td>6</td>
<td>10</td>
<td>3</td>
<td>0</td>
<td>18</td>
<td>A/W d, 1,073+</td>
</tr>
<tr>
<td>8</td>
<td>39/M</td>
<td>NE ALL III</td>
<td>6</td>
<td>13</td>
<td>6</td>
<td>0</td>
<td>21</td>
<td>A/W d, 97, D</td>
</tr>
<tr>
<td>9</td>
<td>18/M</td>
<td>NE ALL III + Cy/MTZ</td>
<td>6</td>
<td>8</td>
<td>38</td>
<td>21</td>
<td>53</td>
<td>A/W d, 145, D</td>
</tr>
<tr>
<td>10</td>
<td>18/M</td>
<td>NE ALL III</td>
<td>7</td>
<td>11</td>
<td>4</td>
<td>6</td>
<td>20</td>
<td>A/W d, 943+</td>
</tr>
<tr>
<td>11</td>
<td>24/F</td>
<td>NE ALL III</td>
<td>8</td>
<td>25</td>
<td>10</td>
<td>4</td>
<td>18</td>
<td>A/W d, 425+</td>
</tr>
<tr>
<td>12</td>
<td>30/M</td>
<td>NE ALL III</td>
<td>6</td>
<td>15</td>
<td>6</td>
<td>10</td>
<td>19</td>
<td>A/W d, 351+</td>
</tr>
<tr>
<td>13</td>
<td>19/M</td>
<td>NE ALL III</td>
<td>9</td>
<td>14</td>
<td>5</td>
<td>2</td>
<td>25</td>
<td>A/W d, 291+</td>
</tr>
<tr>
<td>14</td>
<td>21/M</td>
<td>NE ALL III</td>
<td>23</td>
<td>10</td>
<td>7</td>
<td>7</td>
<td>22</td>
<td>A/W d, 1,591+</td>
</tr>
<tr>
<td>15</td>
<td>18/F</td>
<td>NE ALL III</td>
<td>34</td>
<td>9</td>
<td>7</td>
<td>19</td>
<td>19</td>
<td>A/W d, 1,278+</td>
</tr>
</tbody>
</table>

Patients 14 and 15 who were transplanted after maintenance therapy are not included in the survival figure for the autotransplant group. Survival is calculated from transplant date for each patient.

Abbreviations: DCF, deoxycoformycin; Cy/MTZ, high-dose cytarabine and mitoxantrone; A/W, alive and well; d, days posttransplant; R, relapse; D, died.
groups at 36 months, after which no relapses have occurred in any

conditioning for the ABMT (groups 1 and group IV) was melphalan/TBI
described in text; Standard maintenance was 6-mercaptopurine
and methotrexate for a period of 100 weeks (group I). The late autograft in
in patients 14 and 15 were performed as a result of requests by patients
and attending physicians. Actuarial relapse-free survivals given were
calculated from the time of transplant (Table 1) and assessed for all
groups at 36 months, after which no relapses have occurred in any
group in this cohort.

Abbreviation: NK, not known.

NHL patients. Patients with high-grade NHL with the recog-
nized poor-risk features of Ann Arbor stage 4 disease, bulk (> 10
cm) disease either nodal or extranodal, disease at multiple extran-
odal sites, NHL occurring after previous treatment for Hodgkin's
disease, or risk criteria as described by Coleman et al (lymphoblas-
tic histology with CNS or BM involvement), were autografted after
remission induction treatment. All patients received melphalan
conditioning. TBI was used as well in patients with features
associated with a risk of CNS relapse (ie, lymphoblastic histology,
multiple extranodal sites, or marrow involvement).

NHL patients had remission induced on the SNLG NHL-III
protocol, except for patient 19 who received additional systemic
and intrathecal treatment because of the histologic appearances
of Burkitt's lymphoma. Patients were selected on the above poor-risk
criteria. No patient offered autotransplant declined. For NHL
patients, median time to transplant from diagnosis was 8 months
(range 6 to 14 months), with remission induction chemotherapy
taking 5 months, and local radiotherapy (4 weeks) preceding
autotransplant in patients not receiving TBI.

Autotransplantation Procedure

Bilateral check BM aspirates and trephines were obtained from
the posterior iliac crests to confirm remission and adequate
cellularity 2 to 4 weeks before ABMT. At ABMT, patients were
anesthetized and received 2,000 IU sodium heparin IV. BM was
harvested from the posterior iliac crests into acid citrate dextrose
anticoagulant in standard blood transfusion collection packs, to
yield a median nucleated cell dose of 2.9 x 10^10/kg recipient weight
(range 1.9 to 5.5 kg), and stored at 4°C. Storage for 48 hours under
these conditions does not affect CFU-GM growth in culture (G.H.
Jackson, unpublished observations, 1990). Conditioning proceeded
with melphalan 3 mg/kg body weight by IV infusion immediately

Table 2. NHL ABMT Patients

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Sex</th>
<th>Age/yr</th>
<th>Phenotype</th>
<th>Transplant</th>
<th>Time From</th>
<th>Days of Neutropenia</th>
<th>Days of Platelet Transfusion</th>
<th>Units of Blood Transfusion</th>
<th>Days in Hospital</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>60</td>
<td>Lymphoblastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>9</td>
<td>7</td>
<td>3</td>
<td>3</td>
<td>18</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>58</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>9</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>30</td>
<td>Lymphoblastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>8</td>
<td>5</td>
<td>10</td>
<td>4</td>
<td>20</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>45</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>6</td>
<td>11</td>
<td>10</td>
<td>4</td>
<td>26</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>44</td>
<td>Lymphoblastic</td>
<td>CR2</td>
<td>M/TBI</td>
<td>6</td>
<td>10</td>
<td>1</td>
<td>0</td>
<td>18</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>29</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>7</td>
<td>8</td>
<td>3</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>43</td>
<td>Lymphoblastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>8</td>
<td>11</td>
<td>2</td>
<td>0</td>
<td>18</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>26</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>12</td>
<td>7</td>
<td>1</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>24</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>9</td>
<td>8</td>
<td>1</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>24</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>8</td>
<td>7</td>
<td>2</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>25</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>11</td>
<td>14</td>
<td>8</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>48</td>
<td>Immunoblastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>4</td>
<td>15</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>41</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>8</td>
<td>8</td>
<td>1</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>47</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>14</td>
<td>19</td>
<td>8</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>30</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>11</td>
<td>13</td>
<td>4</td>
<td>2</td>
<td>19</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>64</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>13</td>
<td>14</td>
<td>3</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>21</td>
<td>Diff/C blastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>9</td>
<td>15</td>
<td>5</td>
<td>4</td>
<td>20</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>43</td>
<td>C/cytic/C blastic</td>
<td>CR2</td>
<td>M/TBI</td>
<td>6</td>
<td>12</td>
<td>3</td>
<td>4</td>
<td>18</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>24</td>
<td>Lymphoblastic</td>
<td>CR1</td>
<td>M/TBI</td>
<td>6</td>
<td>12</td>
<td>5</td>
<td>3</td>
<td>24</td>
</tr>
</tbody>
</table>

Abbreviations: Med, mediastinum; A/W, alive and well; d, days posttransplant; D, died; HD, Hodgkin's disease; Diff C blastic, diffuse
centroblastic; C/cytic/C blastic, centrocytic centroblastic; TBI, total body irradiation.

Table 3. ALL Patient Characteristics and Survival Rates

<table>
<thead>
<tr>
<th>Group</th>
<th>Sex</th>
<th>Median Age (yr)/range</th>
<th>Differential</th>
<th>Immuneologc Phenotype</th>
<th>Actuarial Relapse-Free Survival y From Transplant (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I, Standard maintenance (19)</td>
<td>M</td>
<td>32 (14-54)</td>
<td>Male</td>
<td>Common 10</td>
<td>5</td>
</tr>
<tr>
<td>II, Allograft (15)</td>
<td>F</td>
<td>19 (15-40)</td>
<td>Female</td>
<td>Common 15</td>
<td>2</td>
</tr>
<tr>
<td>III, ABMT (13)</td>
<td>M</td>
<td>8 (5-10)</td>
<td>Male</td>
<td>Common 10</td>
<td>2</td>
</tr>
<tr>
<td>IV, Standard maintenance and autograft (2)</td>
<td>M</td>
<td>18</td>
<td>Male</td>
<td>Common 15</td>
<td>2</td>
</tr>
</tbody>
</table>

Characteristics of 49 patients with ALL aged 15 to 65 years achieving sustained remission at 28 weeks from diagnosis. The 15 patients who received allogeneic transplant (group II) received preconditioning with cyclophosphamide (60 mg/kg twice) and TBI (200 cGy six times) in 3
days with cyclosporin alone used as immunosuppression. The precon-
ditioning for the ABMT (groups III and group IV) was melphalan/TBI (described in text); Standard maintenance was 6-mercaptopurine
and methotrexate for a period of 100 weeks (group I). The late autograft in
patients 14 and 15 were performed as a result of requests by patients
and attending physicians. Actuarial relapse-free survivals given were
calculated from the time of transplant (Table 1) and assessed for all
groups at 36 months, after which no relapses have occurred in any
group in this cohort.

Abbreviation: NK, not known.

autotransplant. Additional basic characteristics of the ALL groups
are shown in Table 3.

NHL patients. Patients with high-grade NHL with the recog-
nized poor-risk features of Ann Arbor stage 4 disease, bulk (> 10
cm) disease either nodal or extranodal, disease at multiple extran-
odal sites, NHL occurring after previous treatment for Hodgkin's
disease, or risk criteria as described by Coleman et al (lymphoblas-
tic histology with CNS or BM involvement), were autografted after
remission induction treatment. All patients received melphalan
conditioning. TBI was used as well in patients with features
associated with a risk of CNS relapse (ie, lymphoblastic histology,
multiple extranodal sites, or marrow involvement).

NHL patients had remission induced on the SNLG NHL-III
protocol, except for patient 19 who received additional systemic
and intrathecal treatment because of the histologic appearances
of Burkitt's lymphoma. Patients were selected on the above poor-risk
criteria. No patient offered autotransplant declined. For NHL
patients, median time to transplant from diagnosis was 8 months
(range 6 to 14 months), with remission induction chemotherapy
taking 5 months, and local radiotherapy (4 weeks) preceding
autotransplant in patients not receiving TBI.
other comparable groups (Table 3) DFS for the allograft group was 34%; leukemic relapse and pulmonary toxicity (interstitial pneumonitis and CMV pneumonitis) were responsible for the deaths. No deaths resulted from graft-vs-host disease. The DFS for the standard maintenance group was 21% (Fig 1), with leukemic relapse accounting for all the failures.

Figure 2 shows the relapse-free survival data for the NHL patients. No relapses have occurred in the 17 NHL patients transplanted in CR (curve 1, median follow-up 2 years). One patient, a smoker, died 3 years posttransplant with squamous carcinoma of the lung and without evidence of lymphoma recurrence. This event is responsible for the step in survival curves 1 and 2 at day 1,200 (Fig 2). Curve 2 (Fig 2) relates to all 19 transplanted NHL patients, including the two patients who relapsed before ABMT, both of whom died of progressive disease after transient responses.

DISCUSSION

Most institutions reporting use of ABMT in adult ALL and high-risk lymphoma use cyclophosphamide ± busulfan ± TBI conditioning as well as marrow cryopreservation and, sometimes, purging techniques. Melphalan is an alternative conditioning agent, and its short half-life avoids the necessity for cryopreservation. Melphalan conditioning, however, has been associated with a reported high toxicity: melphalan/TBI was compared with cyclophosphamide/TBI in a study of allogeneic BMT for AML. Results suggested a greater antileukemic effect for melphalan but toxicity in the melphalan arm was very high, with renal failure accounting for most of the excess deaths. Our results indicate that melphalan/TBI conditioning itself is well tolerated and lend support to the suggestion of those investigators that another mechanism, eg, interaction between melphalan...

Table 4. ABMT: Details of Engraftment

<table>
<thead>
<tr>
<th>Conditioning</th>
<th>Melphalan/TBI</th>
<th>Melphalan Alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days of neutropenia (&lt;0.5 × 10⁹/L)</td>
<td>10 (6-25)</td>
<td>11 (3-19)</td>
</tr>
<tr>
<td>Days of platelet transfusion</td>
<td>5 (1-38)</td>
<td>3 (1-10)</td>
</tr>
<tr>
<td>Days in hospital posttransplant</td>
<td>20 (15-53)</td>
<td>18 (13-26)</td>
</tr>
</tbody>
</table>

Comparison of reengraftment after melphalan/TBI conditioning as compared with melphalan alone. Numbers are median numbers of days, with ranges in parentheses.

RESULTS

Hematologic Reconstitution

Marrow reengraftment occurred rapidly in all patients except ALL patient 9, who had prolonged thrombocytopenia. He alone had received high-dose cytarabine and mitoxantrone (Cy/MTZ), before ABMT conditioning. Median number of days of neutropenia (<0.5 × 10⁹/L) was 10 (range 3 to 25 days). Patients required transfusion of platelet concentrates on a median of four occasions (range 1 to 38) and received a median of 3 U (range 0 to 10 U) packed RBC. Reengraftment rates between patients receiving melphalan/TBI and those receiving melphalan alone (Table 4) were not different.

Other Toxicity

Mild oral mucositis was common in patients receiving TBI in addition to melphalan. Twelve of 21 patients in the melphalan/TBI group and 5 of 13 in the melphalan-alone group required IV antibiotics for pyrexial episodes during the transplant admission. No patient had renal failure or interstitial pneumonitis. Patients spent a median of 18 days (range 15 to 53 days) posttransplant in the hospital. There were no procedure-related deaths.

Effect on Disease

Actuarial DFS after autotransplant (calculated from time of transplant) for patients with ALL is 48% with a median follow-up of 2.5 years from time of transplant (Fig 1) (Table 3). This increases to 57% if the two patients transplanted after maintenance therapy are included. Failure in this group resulted entirely from leukemic relapse. In the other comparable groups (Table 3) DFS for the allograft group was 34%; leukemic relapse and pulmonary toxicity (interstitial pneumonitis and CMV pneumonitis) were responsible for the deaths. No deaths resulted from graft-vs-host disease. The DFS for the standard maintenance group was 21% (Fig 1), with leukemic relapse accounting for all the failures.

Figure 2 shows the relapse-free survival data for the NHL patients. No relapses have occurred in the 17 NHL patients transplanted in CR (curve 1, median follow-up 2 years). One patient, a smoker, died 3 years posttransplant with squamous carcinoma of the lung and without evidence of lymphoma recurrence. This event is responsible for the step in survival curves 1 and 2 at day 1,200 (Fig 2). Curve 2 (Fig 2) relates to all 19 transplanted NHL patients, including the two patients who relapsed before ABMT, both of whom died of progressive disease after transient responses.

DISCUSSION

Most institutions reporting use of ABMT in adult ALL and high-risk lymphoma use cyclophosphamide ± busulfan ± TBI conditioning as well as marrow cryopreservation and, sometimes, purging techniques. Melphalan is an alternative conditioning agent, and its short half-life avoids the necessity for cryopreservation. Melphalan conditioning, however, has been associated with a reported high toxicity: melphalan/TBI was compared with cyclophosphamide/TBI in a study of allogeneic BMT for AML. Results suggested a greater antileukemic effect for melphalan but toxicity in the melphalan arm was very high, with renal failure accounting for most of the excess deaths. Our results indicate that melphalan/TBI conditioning itself is well tolerated and lend support to the suggestion of those investigators that another mechanism, eg, interaction between melphalan...

Fig 1. Adult ALL actuarial disease-free survival curves: ABMT, allogeneic, standard maintenance. These curves show the relative survival from the time of transplant in the allogeneic and autologous groups. The curves for standard maintenance start from the time of completion of the 6-month induction schedule. The plateau at which percentage survival figures are given was calculated at 36 months for each curve. A chi-square test of patients who received autotransplant vs patients who had standard maintenance does not currently show a statistically significant difference (P = .35).
Autologous bone marrow transplantation with monoclonal antibody purged marrow for high-risk acute lymphoblastic leukemia.

Promptransplantation in CR1 in a series of patients perceived to be at high risk of relapse on conventional therapy using criteria similar to those identified by Coleman et al. A reluctance to undertake high-dose therapy with BM rescue in CR1 has been expressed,16 however, because of procedure-related mortality rates of approximately 20% in the larger reported series performed in advanced disease16,17 and the difficulty of proving efficacy in patients in CR1 whose outlook is in any case more favorable than that of patients with advanced disease. The relapse-free survival data for our NHL patients suggest a useful efficacy. Proof of that efficacy will require a controlled study and longer follow-up. We have shown, however, that this is a safe approach which merits further study in such patients. We consider that this approach using modest dose intensity can be used when attempting to eradicate minimal residual disease and believe that this philosophy should encourage further investigation of this relatively “gentle” form of autotransplant in CR1 rather than using the very high doses conditioning required for transplants at a later stage of disease.

We conclude that ABMT using melphalan with or without TBI conditioning is a well-tolerated procedure that can be performed safely without the need to cryopreserve marrow. It appears to have a useful efficacy in high-grade lymphoid malignancy in first remission. This form of ABMT in ALL has allowed completion of therapy in a shorter time and led to improved quality of life for the recipients. A trend toward improved duration of disease-free survival is not statistically significant at present. More patients and a larger follow-up will be required to prove whether overall survival will be improved.

REFERENCES


Evans RGB: Acute lymphoblastic leukaemia in the Northern Region of England—A study of 75 cases. Q J Med 57:761, 1985


Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group

PJ Carey, SJ Proctor, P Taylor and PJ Hamilton